News Archive

Niche-specific content is usually not readily available through regular generic search engines. One example is the academic and scholarly content. While running a  search query about an academic topic through a generic search engine such as  Google would probably render fairly decent results, it, however, usually takes digging into so much fluff before finally landing on relevant results. This is where having access to topic-specific search engines comes in handy. Such search engines do not only provide specific content tailored to the topic under study but their content is more likely to be reliable and authoritative. To this end, we have compiled this list of excellent academic search engines that teachers, student researchers and academics can use to quickly locate and access scholarly works and publications. We have only included what we believe are the most relevant and popular titles out there. If you have other suggestions to add to the list please share with us on our Facebook page.

MagBio Genomics, Inc. announces the launch of its new Blood STASIS™ 21- ccfDNA tube for venous whole blood collection and room temperature stabilization of circulating cell-free DNA (ccfDNA).

The Blood STASIS 21-ccfDNA is a direct draw whole blood collection system that contains a proprietary reagent that prevents post-collection release of genomic DNA from white blood cells, resulting in efficient and accurate recovery of ccfDNA with minimal genomic DNA (gDNA) contamination leading to more informative and quality data.

Join Sinai Hospital BioIncubator on Thursday, February 23, 2017, for the second seminar of our Distinguished Speaker Series, sponsored by TEDCO. Keynote speaker Jeff Gibbs, a member of our Innovation Council, will be speaking about the FDA and regulatory affairs.

Event information: When: Thursday, February 23, 2017 from 4:00-5:30pm Location: 2401 W. Belvedere Ave., Baltimore, MD 21215 Room: Phyllis and Leonard J. Attman Board Room (Sinai Hospital Board Room) Parking: Please park in the general hospital parking visitor’s lot, located outside the main entrance of the hospital. This will give you the easiest access to the Phyllis and Leonard J. Attman Board Room.

About The Speaker

Mr. Gibbs is a Director at Hyman, Phelps & McNamara, P.C., Washington, DC, the largest law firm specializing in Food and Drug Administration (FDA) issues. Prior to entering private practice, he served as Associate Chief Counsel for Enforcement at FDA. Mr. Gibbs is currently the chairman of the Food and Drug Law Institute, and he previously served as a member of the George Mason University Human Subjects Review Board. He has written and spoken extensively on FDA issues. Mr. Gibbs graduated from Princeton University and New York University School of Law.

March 14-15, 2017, Washington, DC 

The Office of the National Coordinator for Health Information Technology (ONC), in collaboration with the Chamber of Digital Commerce announces a health standards and data innovation Code-a-Thon.  Code-a-Thon contestants will use open source distributed ledger technology and health-specific standards to address one of the following health IT Tracks:

The Washington DC/Baltimore Chapter of Women In Bio is presenting a program to learn about how bioscience discoveries move from the bench to the market. The route from discovery to market is not linear. Our panelists will relay their experiences with clinical trials, manufacturing, and marketing and will discuss how each of these aspects interacts along the way. Whether you are looking to enter the world of bench to market or are just curious about the process, this will be an informative and fun event. Moderated by Lynn Johnson Langer, Program Director, Sr. Lecturer, Johns Hopkins University, our panel includes the following individuals:

• Neta Nelson – Associate Director, Clinical Operations & Project Management, Technical Resources International, Inc.
• Maura Kahn – Vice President, Business Development and Marketing, Noxilizer, Inc.
• Kathy Webb – Senior Director GMP Operations, Paragon Bioservices, Inc.

Date/Time: Thursday, February 23, 2017 6:00 p.m. – 8:00 p.m. EST

Venue: Johns Hopkins University – Montgomery Campus 106-110 A&R Building 9601 Medical Center Drive Rockville, MD 20850

Thursday, Feb 23 Vigilant Bioservices Open House (UMB Biopark) Come explore our Biorepository then join us for the UMB BioPark Holiday Happy Hour! Tours are from 1:00-5:00pm

Vigilant Bioservices provides GMP storage solutions for Biotech organizations, including outsourced temperature controlled storage and risk mitigation/business continuity services.

If you demand a return on the cost of quality, we offer peace of mind knowing your biomaterials are safe.

A group of scientists and their supporters are set to march Sunday in Boston’s Copley Square in an event they’ve dubbed “a rally to stand up for science” in the Trump years.

Inside a large nearby convention center, meanwhile, the annual meeting of the American Association for the Advancement of Science (AAAS), the United States’ largest general scientific society, has featured speeches and panel sessions further underscoring the sense that under President Trump, scientists could face wide-ranging political conflicts and challenges, and will have to decide how to meet them.

The products that make cities “smart” will be developed, tested and perhaps scaled in our backyard.

A partnership of the Herndon-based Center for Innovative Technology, D.C.-based Smart City Works and 22 CityLink, the master developer of the Gramercy District smart city planned for Ashburn, is accepting applications for its initial cohort of companies in Smart City Works @ Herndon.

OncoImmune, Inc. today announced that is has closed on a $15.0 million Series A round of fundraising led by 3E Bioventures Capital (“3E”).

The new capital will be used primarily to develop a novel clinical stage asset targeting the CD24-Siglec pathway that regulates host inflammatory response to tissue injuries, which has broad implications in the pathogenesis of autoimmune diseases, cancer and graft-versus-host disease (GvHD). OncoImmune will continue clinical testing of its lead clinical product, CD24Fc, in a Phase II trial for the prevention of acute GvHD following myeloablative allogeneic hematopoietic stem cell transplant. CD24Fc has received orphan drug designation for GvHD in both the US and Europe. The funding will also support development of other immuno-oncology (IO) assets with a focus on solid tumor targeting monoclonal antibodies, cancer vaccines, and immunotherapy-related adverse events.

Host:  UM BioPark & Wexford + Technology

Location:  UM BioPark Life Sciences Conference Center 801 W. Baltimore Street Baltimore  Maryland  21201

Time:  5:00pm to 6:30pm

Please join the BioPark’s Monthly Networking Event along with Colleagues from UMBC. Mingle with UM Venture program managers, BioPark tenants, and UMB faculty and staff.